Frequency and Prognostic Value of KRAS, NRAS, and BRAF Mutations in Metastatic Colorectal Cancer: An Iranian Cohort Study
Abbas Eshraghi, Mohammad Sadegh Ghasemi, Jamshid Vafaeimanesh, Mohammad Sina Mirjani, Mostafa Vahedian, Mohammad Reza Ahmadi · 2026
Read Frequency and Prognostic Value of KRAS, NRAS, and BRAF Mutations in Metastatic Colorectal Cancer: An Iranian Cohort Study by Abbas Eshraghi, Mohammad Sadegh Ghasemi, Jamshid Vafaeimanesh, Mohammad Sina Mirjani, Mostafa Vahedian, Mohammad Reza Ahmadi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13680741.txt.
Description
Abbas Eshraghi and co-authors measured three gene mutation rates in advanced colon cancer patients in Iran in a 2026 study. Mutations in the KRAS, NRAS, and BRAF genes shape prognosis and drug choice in this cancer. The team reviewed eighty-three patients with spread disease at one hospital clinic in Qom and checked one-year survival.
KRAS mutations appeared in forty-seven percent of patients, NRAS in about fourteen percent, and BRAF in six percent. BRAF mutations clustered in patients diagnosed under fifty, a link the statistics supported. No mutation tied clearly to sex, tumor site, spread pattern, or one-year survival in this group. The authors note the small cohort limits firm claims and call for larger national studies.
Catalog record
| CREATOR | Abbas Eshraghi, Mohammad Sadegh Ghasemi, Jamshid Vafaeimanesh, Mohammad Sina Mirjani, Mostafa Vahedian, Mohammad Reza Ahmadi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |